Health Diagnostic Laboratory Inc. (HDL, Inc.), announced its partnership to develop a novel laboratory developed test with Gamma Therapeutics, Inc., an Oregon-based biotechnology venture developing diagnostic test and surgical therapy solutions for the cardiovascular disease industry.

Cardiovascular Disease (CVD), Coronary Heart Disease (CHD) and stroke are responsible for 16.7 million, or 29.9 per cent of total global deaths associated with some type of disease, according to the World Health Organization. In 2010, CVD became the leading cause of death in developing countries. At least 20 million people survive heart attacks and strokes every year; many require continuing costly clinical care.

Gamma Therapeutics, launched in November 2010, is bringing to market, in a joint product development effort with HDL, Inc., a novel CVD Risk Assay to enhance cardiologists’ ability to assess heart attack and stroke risk by providing a new predictive and prognostic tool.

The laboratory developed CVD Risk Assay is based upon a naturally occurring clotting protein in human blood called Gamma Prime Fibrinogen, a biomarker strongly associated with cardiovascular disease. The laboratory developed test version of the Gamma Therapeutics’ CVD Assay will be offered exclusively by HDL, Inc., who also will take the lead in BETA testing of the assay for FDA approval.

The Gamma Therapeutics’ executive management team includes David H Farrell, PhD, Founder and CSO and David F. Eastman, MSc, CEO. Its science advisory board is comprised of leading scientists in cardiovascular disease, pathology and haematology research, with expertise in CVD patient medicine and preventative care, cardiovascular surgery, heart attack and stroke risk assessment, clinical and diagnostic testing, surgery-based treatment and business experience in growing biotechnology and medical device ventures.

The launch of the partnership between HDL, Inc. and Gamma Therapeutics represents a combined effort to advance the preventative model for chronic disease management, based on a recent monumental shift in the way physicians test for life-threatening conditions. Moving beyond traditional lipid testing, HDL. Inc. is a market leader in providing comprehensive diagnostics capable of detecting risk factors predisposing patients to cardiovascular disease earlier than ever before possible.

“The results are simple,” said Tonya Mallory, CEO and founder of Virginia-headquartered HDL, Inc. “Thanks to advanced testing, it’s now possible to reveal risk factors and biomarkers for cardiovascular and related diseases. The partnership with Gamma Therapeutics demonstrates HDL, Inc.’s on-going goal to provide best of breed biomarkers, such as this new assay.” Using a systematic approach to identify factors contributing to disease allows HDL, Inc. to provide its physicians with a better basis for effective treatment plans.

Health Diagnostic Laboratory Inc. (HDL, Inc.), a CAP accredited leader in health management, offers a comprehensive test menu of risk factors and biomarkers for cardiovascular and related diseases. Our systematic approach identifies factors contributing to disease and provides a basis for effective personalized treatment, allowing physicians to more effectively manage patients.

Gamma Therapeutics, Inc., is an Oregon biotechnology venture developing a novel class of diagnostic test and surgical therapy solutions for the cardiovascular disease industry. All of its products are based upon a natural protein in blood called Gamma Prime Fibrinogen. Patent-pending and patented products under development include the GammaCoeur CVD Risk Assay, GammaSeal Surgical Incision Sealant and Gammarin Anti-Coagulant Blood Thinner.